
Prostate Cancer
Latest News

Latest Videos

CME Content
More News

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses treatment options for patients with newly diagnosed prostate cancer.

By combining data from genome-wide association studies with epidemiological surveys, investigators say they have developed a genetic tool that can predict age of onset for aggressive prostate cancer.

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses when to give docetaxel as a treatment option for patients with prostate cancer.

Malcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significant results of the PROTECT study for patients with prostate cancer.

Men with newly diagnosed mCRPC in the global LATITUDE trial reported clinical improvements in pain progression, prostate cancer symptoms, fatigue, functional decline, and overallHR-QOL following treatment with abiraterone acetate plus prednisone.

Alicia Morgan, MD, Mather Hospital, discusses the role of PARP inhibitors for patients with prostate cancer.

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, discusses the role of immunotherapy for patients with prostate cancer.

Layering of therapies and advances in next-generation imaging and sequencing are key reasons that outcomes are improving in advanced prostate cancer.

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the advantages and disadvantages of choosing docetaxel as a therapy for patients with mCRPC.

For patients with oligorecurrent prostate cancer, androgen deprivation therapy–free survival was superior for those assigned to metastasis-directed therapy versus surveillance.

One-third of asymptomatic men with metastatic castration-resistant prostate cancer who progressed on enzalutamide (Xtandi) achieved a 50% decline in PSA concentration from baseline (PSA50) following bipolar androgen therapy.

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses tailoring treatment to individual patients with prostate cancer.

Although gene fusions between the TMPRSS2 gene and ETS family of transcription factors in prostate cancer have been recognized for more than a decade, the clinical relevance of this fusion event continues to be debated among experts.

Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the treatment of prostate cancer.

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, discusses the hormone-sensitive setting of prostate cancer.

Men with metastatic castration-resistant prostate cancer who progressed following initial treatment with an androgen receptor-axis-targeted agent had better survival when treated with docetaxel in second-line.

































































